Salinamide F, new depsipeptide antibiotic and inhibitor of bacterial RNA polymerase from a marine-derived Streptomyces sp.

Hassan, Hossam M.; Degen, David; Jang, Kyu‐Ha; Ebright, Richard H.; Fenical, William

doi:10.1038/ja.2014.122

Cited by 46 publications

(23 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CNB-091. 53 To address the bottleneck that oen impedes progress in research, 3D-NMR techniques have been applied to the structure determination of peptidic natural products of interest. To balance costs, yield and relative 13 C/ 15 N abundance the growth media used peptone and yeast extract and 15 NH 4 Cl and [U- 13 C]-glucose.…”

Section: Introductionmentioning

confidence: 99%

Marine natural products

et al. 2017

View full text Add to dashboard Cite

Covering: 2015. Previous review: Nat. Prod. Rep., 2016, 33, 382-431This review covers the literature published in 2015 for marine natural products (MNPs), with 1220 citations (792 for the period January to December 2015) referring to compounds isolated from marine microorganisms and phytoplankton, green, brown and red algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, mangroves and other intertidal plants and microorganisms. The emphasis is on new compounds (1340 in 429 papers for 2015), together with the relevant biological activities, source organisms and country of origin. Reviews, biosynthetic studies, first syntheses, and syntheses that lead to the revision of structures or stereochemistries, have been included.

show abstract

Section: Introductionmentioning

confidence: 99%

Marine natural products

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Hassan and colleagues reported a new depsipeptide salinamide F (11), isolated from a marine-derived Streptomyces sp. strain CNB-091 that was observed to significantly inhibit RNA polymerase (RNAP) from both Gram-positive and Gram-negative bacteria, but "does not interact with the rifampin binding site on RNAP" [32].…”

Section: Antibacterial Activitymentioning

confidence: 99%

Marine Pharmacology in 2014–2015: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, Antiviral, and Anthelmintic Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

et al. 2019

View full text Add to dashboard Cite

The systematic review of the marine pharmacology literature from 2014 to 2015 was completed in a manner consistent with the 1998–2013 reviews of this series. Research in marine pharmacology during 2014–2015, which was reported by investigators in 43 countries, described novel findings on the preclinical pharmacology of 301 marine compounds. These observations included antibacterial, antifungal, antiprotozoal, antituberculosis, antiviral, and anthelmintic pharmacological activities for 133 marine natural products, 85 marine compounds with antidiabetic, and anti-inflammatory activities, as well as those that affected the immune and nervous system, and 83 marine compounds that displayed miscellaneous mechanisms of action, and may probably contribute to novel pharmacological classes upon further research. Thus, in 2014–2015, the preclinical marine natural product pharmacology pipeline provided novel pharmacology as well as new lead compounds for the clinical marine pharmaceutical pipeline, and thus continued to contribute to ongoing global research for alternative therapeutic approaches to many disease categories.

show abstract

“…A traditional approach in obtaining novel bioactive agents, especially with unique chemical structures and biological significance, relies on distinct microorganisms isolated from different, often secluded, environments. Actinobacterial strains commonly derive from soil (Guo et al 2015), but they are also abundantly present in seas and oceans (Hassan et al 2015;Xu et al 2017). Moreover, extreme habitats such as caves (Jiang et al 2015), deserts (Goodfellow et al 2017) or Antarctic ecosystems (Lee et al 2012) are recognized as valuable sources of actinomycetes producing novel metabolites of pharmacological importance (Solecka et al 2013;Singh et al 2018).…”

Section: Introductionmentioning

confidence: 99%

“…The activity profile of salinamide F revealed that it is active towards E. coli D21f2tolC, Haemophilus influenzae, E. faecalis and Neis seria gonorrhoeae with MIC values of 0.20, 12.5, 12.5 and 25 μg/ml, respectively. Moreover, it showed significant inhibition of Gram-positive and Gram-nega tive bacterial RNA polymerase with IC 50 = 4 μM for S. aureus RNAP and 2 μM for E. coli RNAP (Hassan et al 2015).…”

mentioning

confidence: 99%

Secondary Metabolites of Actinomycetes and their Antibacterial, Antifungal and Antiviral Properties

Jakubiec-Krześniak

Rajnisz-Mateusiak

Guśpiel

et al. 2018

Polish Journal of Microbiology

116

View full text Add to dashboard Cite

The growing resistance of microorganisms towards antibiotics has become a serious global problem. Therapeutics with novel chemical scaffolds and/or mechanisms of action are urgently needed to combat infections caused by multidrug resistant pathogens, including bacteria, fungi and viruses. Development of novel antimicrobial agents is still highly dependent on the discovery of new natural products. At present, most antimicrobial drugs used in medicine are of natural origin. Among the natural producers of bioactive substances, Actinobacteria continue to be an important source of novel secondary metabolites for drug application. In this review, the authors report on the bioactive antimicrobial secondary metabolites of Actinobacteria that were described between 2011 and April 2018. Special attention is paid to the chemical scaffolds, biological activities and origin of these novel antibacterial, antifungal and antiviral compounds. Arenimycin C, chromopeptide lactone RSP 01, kocurin, macrolactins A1 and B1, chaxamycin D as well as anthracimycin are regarded as the most effective compounds with antibacterial activity. In turn, the highest potency among selected antifungal compounds is exhibited by enduspeptide B, neomaclafungins A-I and kribelloside D, while ahmpatinin i Bu, antimycin A1a, and pentapeptide 4862F are recognized as the strongest antiviral agents.

show abstract

Salinamide F, new depsipeptide antibiotic and inhibitor of bacterial RNA polymerase from a marine-derived Streptomyces sp.

Cited by 46 publications

References 14 publications

Marine natural products

Marine natural products

Marine Pharmacology in 2014–2015: Marine Compounds with Antibacterial, Antidiabetic, Antifungal, Anti-Inflammatory, Antiprotozoal, Antituberculosis, Antiviral, and Anthelmintic Activities; Affecting the Immune and Nervous Systems, and Other Miscellaneous Mechanisms of Action

Secondary Metabolites of Actinomycetes and their Antibacterial, Antifungal and Antiviral Properties

Contact Info

Product

Resources

About